Close X
Attorney Spotlight

How did Mike DeAgro's experience co-founding a nonprofit advocacy organization lead to a career in the legal field? Find out more>


Close X


Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more

Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

The Landscape Shifts for Pharmaceutical Patents as the Supreme Court and Federal Circuit Review PTAB IPR Decisions


December 13, 2016

The pharmaceutical patent landscape is undergoing changes as the Supreme Court of the United States and the Federal Circuit review an increasing number of Patent Trial and Appeal Board inter partes review proceeding decisions. While the appellate courts give some deference to the PTAB's implementation of the America Invents Act, we are seeing more dissenting opinions and some panels are striking down the PTAB's interpretation of the AIA. During this webinar, Janelle Waack and Greg Parker will highlight relevant trends, address issues and offer insights pertinent to the pharmaceutical industry.

Topics will include:

  • Addressing Supreme Court and Federal Circuit decisions impacting IPR claim interpretation, expert testimony, amendment of claims, estoppel, burden shifting and raising new arguments in reply briefs
  • An overview of how to preserve issues in the IPR record for appeal 
  • The impact of recent Supreme Court and Federal Circuit decisions on strategies for pharmaceutical patents undergoing review at the PTAB

For more information and registration, visit the IP Counsel Exchange website.

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.